Our new discovery research strategy aims at further enhancing our capacity for innovation and at encouraging scientific creativity for diseases with high unmet medical need. It is based on three pillars:
Four Discovery Research Therapeutic Areas
Build on our strengths in R&D by focusing on core diseases for which we have built expertise over time and are actively investing from early research, through clinical development, to the market phase.
Focus on highly dynamic research fields such as immune modulation and regenerative medicine which may impact and create synergies among several of our Discovery Research Therapeutic Areas.
Research Beyond Borders
Explore emerging science and technology for but also beyond our Discovery Research Therapeutic Areas in order to prepare a timely and efficient entry into emerging new medical and scientific fields and technologies.
Opportunities for effective drug discovery in oncology have never been better. Blueprints of the genetic and biochemical workings of cancer cells allow scientists in our laboratories to focus on promising targets for potential new therapeutic approaches. The impact of modern cancer genetics and immunotherapy on drug discovery is already changing the practice of medicine in oncology, with both biopharmaceuticals and small-molecules contributing to a growing repertoire of therapies.
Our fully integrated drug discovery centre in Vienna, Austria has more than 250 scientists with extensive capabilities in both small molecule and biotherapeutic discovery. A large number of collaborations with both academic partners and biotechnology companies are supporting our search for novel targets, biomarkers, drug candidates and treatment modalities.